Many young men who survive cancer are damaged by the treatment. This study sought to find the magnitude of the risk of testicular damage.
The aim of this study was to evaluate the risk of presenting with biochemical signs of hypogonadism in testicular cancer survivors (TCS) and male childhood cancer survivors (CCS) in relation to the type of treatment given. Hypogonadism was found in 26% of CCS and 36% of TCS, respectively
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
